Cholesterol Crystal Embolism and Chronic Kidney Disease
AbstractRenal disease caused by cholesterol crystal embolism (CCE) occurs when cholesterol crystals become lodged in small renal arteries after small pieces of atheromatous plaques break off from the aorta or renal arteries and shower the downstream vascular bed. CCE is a multisystemic disease but kidneys are particularly vulnerable to atheroembolic disease, which can cause an acute, subacute, or chronic decline in renal function. This life-threatening disease may be underdiagnosed and overlooked as a cause of chronic kidney disease (CKD) among patients with advanced atherosclerosis. CCE can result from vascular surgery, angiography, or administration of anticoagulants. Atheroembolic renal disease has various clinical features that resemble those found in other kidney disorders and systemic diseases. It is commonly misdiagnosed in clinic, but confirmed by characteristic renal biopsy findings. Therapeutic options are limited, and prognosis is considered to be poor. Expanding knowledge of atheroembolic renal disease due to CCE opens perspectives for recognition, diagnosis, and treatment of this cause of progressive renal insufficiency. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Li, X.; Bayliss, G.; Zhuang, S. Cholesterol Crystal Embolism and Chronic Kidney Disease. Int. J. Mol. Sci. 2017, 18, 1120.
Li X, Bayliss G, Zhuang S. Cholesterol Crystal Embolism and Chronic Kidney Disease. International Journal of Molecular Sciences. 2017; 18(6):1120.Chicago/Turabian Style
Li, Xuezhu; Bayliss, George; Zhuang, Shougang. 2017. "Cholesterol Crystal Embolism and Chronic Kidney Disease." Int. J. Mol. Sci. 18, no. 6: 1120.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.